ILW.COM - the immigration portal Immigration Daily

Immigration Daily: the news source for legal professionals. Free! Join 35000+ readers

Home Page

Advanced search


Immigration Daily

Archives

Processing times

Immigration forms

Discussion board

Resources

Blogs

Twitter feed

Immigrant Nation

Attorney2Attorney

CLE Workshops

Immigration books

Advertise on ILW

VIP Network

EB-5

Chinese Immig. Daily

About ILW.COM

Connect to us

Make us Homepage

Questions/Comments


SUBSCRIBE

Immigration Daily

 

Chinese Immig. Daily



The leading
immigration law
publisher - over
50000 pages of free
information!

Copyright
©1995-
ILW.COM,
American
Immigration LLC.

Immigration Daily: the news source for
legal professionals. Free! Join 35000+ readers
Enter your email address here:



< Back to current issue of Immigration Daily

Immigrants Of The Week: Charles Mullighan, Mauro Fiore

by Greg Siskind

IMMIGRANT OF THE DAY: CHARLES MULLIGHAN - CANCER RESEARCHER

 
St. Jude Children's Hospital is known throughout the world for its groundbreaking research relating to childhood cancer. One of their stars is Australian-born Charles Mullighan who has gained attention for discovering what is described as "the missing piece" in the puzzle of genetic mutations that contribute to the onset of childhood leukemia.

Mullighan recently described his work to the Memphis Business Journal:

“The most common childhood cancer,” says Mullighan, “is ALL, a genetic disease.” He explains that ALL stops normal white blood cells, which constitute the body’s natural immune system, from growing; without adequate natural immunity, infections eventually overwhelm and kill the patient.

Mullighan says that, while 94% of ALL sufferers are now cured at St. Jude (up tremendously from the 4% cure rate when the hospital opened nearly five decades ago), there is still the remaining 6% who are not cured and as much as 25% who relapse years later.

“We want 100%,” Mullighan says of the institution’s goal to cure ALL. And the discovery of genetic lesions peculiar to ALL patients is leading to applications in other types of cancers.